01 Nov NuVision
NuVision’s therapy, Omnigen, is based on research carried out at the University of Nottingham by Dr Andrew Hopkinson. It harnesses the regenerative properties of amniotic membrane which surrounds babies in the womb and is normally discarded at birth. The company, which is based at MediCity, Nottingham has also developed a bespoke contact lens product, OmniLenz®, that allows Omnigen to be applied in a five-minute procedure in outpatient clinics, eliminating the need for surgery and sutures. Trials are taking place at Aston University. BioCity joined the MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia and part of the Midlands Engine Investment Fund; Mercia’s own funds and the University of Nottingham to complete the £1.4m funding round.